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A total of 184 methicillin-resistant Staphylococcus
aureus (MRSA) strains were collected from patients who
sought treatment primarily for skin and soft tissue infections
from January 1, 1999, to March 31, 2002, in east-central
Saskatchewan, Canada. Molecular subtyping analysis
using pulsed-field gel electrophoresis showed 2 major clus-
ters. Cluster A(n = 55) was composed of a multidrug-resist-
ant MRSA strain associated with a long-term care facility
and was similar to the previously reported nosocomial
Canadian epidemic strain labeled CMRSA-2. Cluster B (n =
125) was associated with cases identified at community
health centers and was indistinguishable from a communi-
ty-associated (CA)-MRSA strain identified previously in the
United States (USA400). Cluster B remained susceptible to
a number of classes of antimicrobial agents and harbored
the lukF-PV and lukS-PV toxin genes. Over 50% of both
clonal groups displayed high-level resistance to mupirocin.
This is the first report of the USA400 strain harboring the
lukF-PV and lukS-PV toxin genes in Canada. 
T
he first report of a highly virulent community-acquired
methicillin-resistant  Staphylococcus aureus (CA-
MRSA) strain occurred in 1993 in Australia (1), and since
that time CA-MRSA has been reported in many countries.
CA-MRSA strains are different genetically and epidemio-
logically from strains commonly associated with nosoco-
mial infections. Common nosocomial risk factors generally
do not apply to CA-MRSA, although previous antimicro-
bial drug use has been identified as a potential risk factor
for CA-MRSA(2–4). In addition, reports have documented
CA-MRSA as having caused serious, and sometimes fatal,
disease, especially in otherwise healthy children (5–7).
Most CA-MRSA strains remain susceptible to a number of
classes of antimicrobial agents such as aminoglycosides,
tetracyclines, and fluoroquinolones. Many reports of CA-
MRSA have described strains harboring the Panton-
Valentine leukocidin determinant, a virulence factor for
primary skin infection and pneumonia (8,9).
Over the past decade, MRSA has been observed spo-
radically as a community-acquired pathogen in Canada
(10,11). On the Canadian prairies a disproportionate num-
ber of aboriginal persons admitted to acute care facilities
are infected or colonized with MRSA, compared to per-
sons of nonaboriginal origin (10,12).
This report describes the emergence of 2 different
strains of MRSA in east-central Saskatchewan, Canada.
The first was associated with a long-term care facility and
the second was a clone of MRSA harboring the lukF-PV
and lukS-PV toxin genes and generated an indistinguishable
fingerprint from the previously described USA400 strain.
This is the first report describing the emergence in Canada
of the strain of USA400 that contains lukF-PVand lukS-PV.
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Setting
The investigation focused on an area in east-central
Saskatchewan. This region consisted of a city of ≈7,127
persons that was serviced by a hospital with a central lab-
oratory in which the MRSA strains were identified. This
locale also contained a number of community health cen-
ters and a long-term care facility housing ≈100 persons.
The region also included a number of smaller communities
that consisted of small rural First Nations and Metis com-
munities (aboriginal populations) and small towns. 
Case Definitions 
Surveillance for MRSA was laboratory-based and
involved nonrepeat MRSA cases. Case-patients were resi-
dents of east-central Saskatchewan with laboratory-con-
firmed MRSA infections identified from January 1, 1999,
to March 31, 2002, by the local hospital or provincial lab-
oratory. All MRSA isolates identified by the hospital labo-
ratory were subsequently confirmed at the provincial
laboratory by using standard protocols. Residential status
was determined by the location of the patient’s treatment
facility because case-patient address information was
unavailable. General patient demographic information was
collected (date of birth, sex, date of sample collection, and
invasiveness) for all case-patients. Invasive infections
were defined according to the guidelines from the Centers
for Disease Control and Prevention Active Bacterial Core
Surveillance Program and included obtaining isolates from
a normally sterile site, such as blood, cerebrospinal fluid,
pleural fluid, peritoneal fluid, pericardial fluid, surgical
aspirate, bone, joint fluid, or internal body site
(www.cdc.gov/ncidod/dbmd/abcs/meth-case.htm).
Antimicrobial susceptibility testing by microbroth dilution
was performed according to NCCLS recommendations
(13). Breakpoints used for mupirocin were as follows: sus-
ceptible, MIC <4 mg/L; low-level resistance, MIC >4 and
<256 mg/L; high-level resistance, >256 mg/L (14). 
Molecular Characterization of MRSA Strains
mecA and nuc genes from MRSA isolates were coam-
plified with a multiplex real-time polymerase chain reac-
tion (PCR) assay. Nucleic acid was isolated from 4–5
colony picks by boiling in a 2% (wt/vol) homogeneous
suspension of Chelex 100 resin (Bio-Rad Laboratories Ltd,
Mississauga, Ontario, Canada). Primer and probe
sequences with their reaction concentrations are shown in
Table 1. Master mix was composed of the Applied
Biosystems TaqMan PCR Core kit (Applied Biosystems,
Foster City, CA, USA) that uses reaction concentrations
of: 1x PCR buffer A, 4.0 mmol/L MgCl2, 200 µmol/L
dATP, 200 µmol/L dCTP, 200 µmol/L dGTP, 400 µmol/L
dUTP, 1.25 U AmpliTaq Gold, and 0.5 U uracil-DNA-N-
glycosylase (UNG) for carryover prevention. Thermal
cycling and data collection were performed on an ABI
Prism 7700 Sequence Detector using the following condi-
tions: 2 min at 50°C, 10 min at 95°C, followed by 55
cycles of 95°C for 15 s and 60°C for 1 min. Amplification
was confirmed for each target by the generation of a sig-
moid amplification plot.
lukF-PV and  lukS-PV detection was carried out by
using PCR with primers and protocols previously
described (15). PCR was used to detect the exfoliative
toxin genes eta and etb as previously described (16).
Isolates were subtyped by using pulsed-field gel elec-
trophoresis (PFGE) after digestion with SmaI following
the Canadian Standardized Protocol as described previous-
ly (17). PFGE-generated DNA fingerprints were digitized
and analyzed with BioNumerics Ver. 3.5 (Applied Maths,
Sint-Martens-Latem, Belgium) by using a position toler-
ance of 1.0 and an optimization of 1.0. Relatedness was
determined following established criteria with major strain
clusters (designated by a letter) grouped with banding pat-
terns of <7 band changes (18). Fingerprints were compared
to those in the national MRSA fingerprint database, which
comprised of >600 unique MRSA fingerprint types.
Isolates with specific DNAprofiles were grouped into 1 of
6 Canadian epidemic strains of MRSA (CMRSA-1,
CMRSA-2, CMRSA-3, etc.) as previously described
(19,20). Multilocus sequence typing (MLST) was conduct-
ed on a representative isolate from each of the unique
PFGE types as previously described (21). Staphylococcal
chromosome cassette (SCC) mec typing was conducted as
previously described (22).
Results
Epidemiologic Analysis of MRSA
Before 1999, MRSA was rarely isolated in east-central
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sons from this region since 1996. However, in April 1999,
a resident of a long-term care facility in the region under
study tested positive for MRSA. This patient had recently
been hospitalized in Saskatoon, Saskatchewan, and tested
positive for MRSA shortly after being transferred back to
the long-term care facility. Following this case, an addi-
tional 183 nonrepeat MRSA were isolated from infected
persons from this region between January 1999 and April
2002. The annual rates of MRSA-related infections in the
region under study were 3.1/1,000 persons in 1999,
4.8/1,000 persons in 2000, and 14.6/1,000 persons in 2001.
In 1 specific community within the study area with a pop-
ulation of approximately 1,400 persons, MRSA rates were
0/1,000 in 1999, 7.1/1,000 in 2000, and 46/1,000 in 2001.
Only a single isolate was considered invasive, having
causes a blood infection. Approximately 18% (n = 33) of
the cases were identified from a single long-term care
facility and made up of >50% of cases identified between
April 1999 and June 2000 (Figure 1A). After June 2000, a
larger cluster of cases emerged, which peaked in October
2001 and were primarily identified from patients present-
ing at local health clinics or nursing stations from sur-
rounding communities (Figure 1A).
Molecular Characterization of MRSA
All of the 184 strains were PCR positive for the mecA
and  nuc genes, respectively. DNA fingerprinting of all
strains using PFGE resulted in the identification of 5 major
fingerprint patterns labeled pattern A to E (Figure 2).
Clonal group A (n = 55) comprised 8 subtypes with sub-
type A1 representing 86% (n = 47, Canadian Diseases
Network (CDN) type 417) of the total, with other A sub-
types as follows: A2 (n = 1, CDN type 697); A3 (n = 1,
CDN type 695); A4 (n = 2, CDN type 691); A5 (n = 1,
CDN type 696); A6 (n = 1, CDN type 550); A7 (n = 1,
CDN type 726); A8 (n = 1, CDN type 725). Group B was
the most predominant molecular subtype with 68% (n =
126) of the strains in this cluster. This group was com-
prised of 3 PFGE subtypes labeled B1 (n = 123, CDN type
142), B2 (n = 1, CDN type 378), and B3 (n = 2, CDN type
418). Three additional unique PFGE fingerprint types were
labeled C1 (n = 1, CDN type 494), D1 (n = 1, CDN type
334), and E1 (n = 1, CDN type 147). 
Characterization of Clonal Group A Isolates
Clonal group A isolates were first identified on April
12, 1999, from a patient in a long-term care facility who
had been transferred from a hospital in Saskatoon,
Saskatchewan. Arapid increase in cases was related to this
clonal group from persons from the long-term care facility
(n = 33, 60%) as well as community health centers (n = 22,
40%) during the next few months (Figure 1B). Cases relat-
ed to this group peaked June 1999; however, isolates con-
tinued to be identified over the course of this study from
both patients in long-term care facilities and community
health centers (Figure 1). Clonal group A strains were
found to cause a large number of noninvasive infections.
Only a single isolate was identified as causing an invasive
blood infection. A slightly higher number of female
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Figure 1. Epidemiologic curve showing the emergence of methi-
cillin-resistant Staphylococcus aureus (MRSA) in central-eastern
Saskatchewan. A) Number of nonrepeat cases over the length of
study; solid bars, cases identified in a long-term care facility; gray
bars, cases identified in community health centers. B) Same data
as (A), with solid bars representing isolates of clone A and gray
bars showing isolates of clone B.patients 58% (n = 32) were identified with clonal group
A–related infections. Approximately 64% (n = 35) of these
strains were identified from persons >59 years of age,
although 29% (n = 16) of cases were identified in persons
<10 years of age (Figure 3). Of the 22 cases reported from
the community health centers, 73% (n = 16) were <18
years of age. Comparison of the representative PFGE clon-
al group A1 fingerprint pattern to the Canadian National
Fingerprint Database showed that these strains were simi-
lar to the previously identified epidemic MRSA-labeled
CMRSA-2 (19,20). A representative strain from each of
the unique fingerprint patterns from the Aclonal group was
typed by using MLST, and all were found to be of the
sequence type ST5. All of the unique Asubtypes as well as
a 25% (n = 12) sample of strains that were of the A1 sub-
type did not harbor the lukF-PV, lukS-PV, eta, and etb
toxin genes. SCCmec typing of 4 A1 subtypes and sub-
types A2, A3, A4, A5 showed all contained SCCmec IIIb.
Most clonal group A isolates were resistant to
ciprofloxacin, erythromycin, gentamicin, tetracycline,
mupirocin, and fusidic acid (Table 2).
Characterization of Clonal Group B Isolates
The first reported case of infection due to clonal group
B occurred 16 months after the description of first report-
ed MRSAinfection on August 31, 2000, and the cases con-
tinued to increase with a peak of occurring in October
2001 (Figure 1B). Clonal group B correlated with a large
number of noninvasive infections reported from communi-
ty health centers, and only 1 report was made of a long-
term care patient with MRSA type 0142 infection. The
distribution by sex was similar; 49% of patients were
female (n = 62) and 51% were male (n = 64). More than
67% (n = 85) of these strains were identified from persons
<20 years of age, although ≈17% (n = 21) of cases were
identified in persons >40 years (Figure 3). 
The PFGE B1 fingerprint pattern (CDN type 142) was
indistinguishable from the USA CA-MRSA strain labeled
USA400 (Figure 2) (21). MLST was conducted on 1 rep-
resentative strain from each clonal group B subtype, and
all were the same sequence type (ST1). In addition, these
MRSA strains were shown to contain SCCmec type IV. A
selection of ≈25% of the PFGE type 142 strains (n = 33),
including all of the unique fingerprint patterns B2 and B3,
was shown by PCR to harbor the lukF-PV and lukS-PV
genes, and none of the strains tested harbored the eta and
etb toxin genes. Clonal group B strains were susceptible to
most antimicrobial agents tested; however, 40% and 55%
of the isolates displayed resistance to erythromycin and
high-level resistance to mupirocin, respectively (Table 2). 
Characterization of Other Molecular Subtypes
Three other unique PFGE subtype groups were identi-
fied; these were composed of single isolates labeled C1,
D1, and E1, respectively (Figure 2). None of these isolates
carried the lukF-PV and  lukS-PV toxin genes or the
Methicillin-resistant Staphylococcus aureus, Canada
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Figure 2. A) Pulsed-field gel elec-
trophoresis (PFGE) fingerprint of
USA400 and PFGE pattern B1.
B) Dendrogram showing relation-
ship of the unique fingerprints,
along with the PFGE type desig-
nation (11) and other molecular
characteristics of each subtype.
CDN, Canadian Diseases
Network; MLST, multilocus
sequence typing; SCC, staphylo-
coccal chromosome cassette.
Figure 3. Age distribution of patients with cases caused by each
clonal type A (white bars) or type B (black bars).exfoliative toxins. Similar to the PFGE B clonal group,
these strains remained susceptible to most non–β-lactam
drugs tested (data not shown).
Discussion
Adramatic increase of MRSAin the east-central region
of Saskatchewan has been documented in this study.
Molecular typing analysis has shown that 2 major unrelat-
ed strain clusters were in circulation in the communities
under study. The emergence of clonal group A was linked
to a patient in a long-term care facility who had recently
been transferred from a hospital in Saskatoon, and this
strain began to spread within the facility. Comparisons to
the Canadian National Fingerprint Database showed the
A1 pattern is related to the CMRSA-2 epidemic strain
cluster observed in Canadian tertiary care hospitals
(19,20). Forty percent of infections caused by the A clonal
group were identified from community health centers,
which suggests that this strain may have spread from the
long-term care facility into the community. In fact,
CMRSA-2 has been previously shown to be more likely to
be associated with community isolations than the other
epidemic CMRSA clusters (19). Unlike previously
described CA-MRSA strains, this strain does not harbor
the PVL or exfoliative toxin genes, and it displays a mul-
tidrug resistance phenotype. However, analysis of the
community health center cases showed that most (73%)
were from persons <18 years of age. Current studies that
use comparative genomics are under way in our laborato-
ry to determine whether any genetic differences exist
between community, nosocomial, and sporadic MRSAthat
may explain the association with community isolation
(23). 
The more predominant clone (cluster B) in this study
was, with 1 exception, identified from cases reported from
community health centers. Comparison of the B1 finger-
print pattern showed that it was indistinguishable to the
USA400 strain, which is responsible for CA-MRSAinfec-
tions in the midwestern United States (24,25). Although
the source of the USA 400 strain into this community can-
not be determined, a community-based cluster of MRSA
was reported in a rural community in southwestern
Manitoba in 1997, and this strain had been identified pre-
viously from persons in northwestern Manitoba since 1995
(26). We have demonstrated that this strain is also indistin-
guishable from the USA400 fingerprint pattern (data not
shown). This strain may have spread from northwestern
Manitoba to the community in this current study because
they are geographically close (J. Wylie, pers. comm.). 
When all of the typing information is compared, some
observations warrant mention. The single isolate with the
molecular subtype designated A6 contains SCCmec IV,
which is different from the other A-subtypes that contain
SCCmec IIIb. Notably, all A-subtypes are clustered into
the MLST group ST5. Although the SCCmec IV region is
smaller than that of the SCCmec IIIb, it could not have
arisen from a simple deletion event because sequence
analysis of these 2 cassettes has shown l significant differ-
ence that cannot be explained by a simple deletion event
(27). One possible explanation is that a recombinational
event occurred, which led to the replacement of SCCmec
IIIb with the SCCmec IV. Instability in these regions has
been reported, although the events are likely rare (28,29).
Since clone B harboring the SCCmec IV is also circulating
in this community, a recombination event may have
occurred. Furthermore, the MRSA strains with macrore-
striction patterns C1 and D1 also contained the SCCmec
IV region, which suggests that horizontal transfer of this
cassette to additional S. aureus strains may have occurred.
Alternatively, the strain with the A6 pattern may have
emerged independently from the other strains within the A
cluster. 
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mupirocin resistance in >50% of all study strains (clones A
and B). Mupirocin can be used to treat superficial skin
infections and has been used to decolonize patients. High-
level mupirocin resistance in MRSA was first described in
1996 among patients in a burn unit in Kuwait (30).
Mupirocin resistance is mediated by the mupA gene, which
is generally plasmid encoded, although recently the gene
has been identified on the chromosome of S.  aureus
(30,31). Since high-level resistance has been documented
on plasmids that vary in size and restriction patterns (1,32),
examining the plasmid restriction fragment length poly-
morphisms may be useful in monitoring monitor plasmid
dissemination between and within the clonal types. In a
similar manner, we previously described  extended-spec-
trum  β-lactamase–containing plasmids in gram-negative
organisms (33). Information from this exercise could
determine if horizontal transfer of the gene coding for
mupirocin resistance occurred between the two clonal
groups A and B. 
We retrospectively reviewed a sample of charts from
patients with skin and soft tissue infections in 2002 in the
region of highest CA-MRSA frequency and found that
18% of these infections resulted in a prescription for
mupirocin (unpub. data). The use of mupirocin in these
communities may be driving resistance. A recent study of
patients from a Tennessee medical center documented that
decreased usage of mupirocin reduces this form of resist-
ance in MRSA (33). We are currently developing educa-
tional programs to decrease the use of this drug, which we
hope will decrease mupirocin resistance in this region. 
The 2 clonal groups of MRSA described in this study
continue to circulate in this area of Saskatchewan (data not
shown). We are currently undertaking a case-control study
to identify risk factors associated with infections caused by
these 2 strains in the community. We call for future studies
to include mupirocin in their antimicrobial resistance pan-
els because resistance to this agent may affect treatment
outcomes.  
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